open access

Vol 83, No 6 (2012)
ARTICLES
Get Citation

Expression of metalloproteinase MMP-9 and tissue inhibitor of metalloproteinase TIMP-2 in placenta of pregnant women with intrauterine growth restriction

Arkadiusz Świerczewski, Józef Kobos, Jacek Pasiński, Urszula Kowalska-Koprek, Agata Karowicz-Bilińska
Ginekol Pol 2012;83(6).

open access

Vol 83, No 6 (2012)
ARTICLES

Abstract

Introduction: The development of pregnancy depends on many factors, among other the implantation and the development of the placenta and placental vascularity. The correct course of these processes depends on the proper activity of the enzymes degradating elements of extracellular matrix and basal membrane – metalloproteinases. Objectives: Assessment of the expression of MMP-9 and TIMP-2 in the placenta of women with intrauterine fetal growth restriction. Material and methods: Two study groups were distinguished - with untreated IUGR and with IUGR treated with the acetylsalicylic acid and L-arginine and the control group with correct fetal growth and course of pregnancy. Marked microscope preparations from placental samples were made with specific antibodies for MMP-9 and TIMP-2. Results: The greatest intensity of the reaction and the villous TIMP-2 expression was characteristic of the group with untreated IUGR. Strongest expression MMP-9 was observed in the control group. The smallest surface of the trophoblast with positive MMP-9 reaction appeared in the group with untreated IUGR. Conclusions: High MMP-9 activity in the placenta correlates with its correct structure and function. Application of IUGR treatment reduces the expression of TIMP-2 in the placental villi.

Abstract

Introduction: The development of pregnancy depends on many factors, among other the implantation and the development of the placenta and placental vascularity. The correct course of these processes depends on the proper activity of the enzymes degradating elements of extracellular matrix and basal membrane – metalloproteinases. Objectives: Assessment of the expression of MMP-9 and TIMP-2 in the placenta of women with intrauterine fetal growth restriction. Material and methods: Two study groups were distinguished - with untreated IUGR and with IUGR treated with the acetylsalicylic acid and L-arginine and the control group with correct fetal growth and course of pregnancy. Marked microscope preparations from placental samples were made with specific antibodies for MMP-9 and TIMP-2. Results: The greatest intensity of the reaction and the villous TIMP-2 expression was characteristic of the group with untreated IUGR. Strongest expression MMP-9 was observed in the control group. The smallest surface of the trophoblast with positive MMP-9 reaction appeared in the group with untreated IUGR. Conclusions: High MMP-9 activity in the placenta correlates with its correct structure and function. Application of IUGR treatment reduces the expression of TIMP-2 in the placental villi.
Get Citation

Keywords

pregnancy, Placenta, metalloproteinases

About this article
Title

Expression of metalloproteinase MMP-9 and tissue inhibitor of metalloproteinase TIMP-2 in placenta of pregnant women with intrauterine growth restriction

Journal

Ginekologia Polska

Issue

Vol 83, No 6 (2012)

Page views

518

Article views/downloads

1321

Bibliographic record

Ginekol Pol 2012;83(6).

Keywords

pregnancy
Placenta
metalloproteinases

Authors

Arkadiusz Świerczewski
Józef Kobos
Jacek Pasiński
Urszula Kowalska-Koprek
Agata Karowicz-Bilińska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl